ライフサイエンスコーパス: antineoplastic drug

1 making the tumor cells further resistant to antineoplastic drugs.

2 ity and alter the pharmacokinetic profile of antineoplastic drugs.

3 ffects of reactive oxygen species-generating antineoplastic drugs.

4 lective, small-molecule kinase inhibitors as antineoplastic drugs.

5 ng strategies as a means of developing novel antineoplastic drugs.

6 c target for a number of clinically relevant antineoplastic drugs.

7 clinical studies of anti-HER2 SL loaded with antineoplastic drugs.

8 so induced partial cross-resistance to other antineoplastic drugs.

9 gest a potential role for S-nitrosylation in antineoplastic drug action.

10 late kinase is involved in antimicrobial and antineoplastic drug activation.

11 nged exposure of lung-resident tumors to the antineoplastic drug and reduced local toxicity.

12 pression also modulates the effects of other antineoplastic drugs and whether it is associated with a

13 ay be most useful when "metronomic" doses of antineoplastic drugs are used, thereby potentially avoid

14 tudy, we monitored the cellular responses to antineoplastic drug at a single cell basis with Raman sp

15 Exisulind (Aptosyn) is a novel antineoplastic drug being developed for the prevention a

16 nvolved in the metabolic inactivation of the antineoplastic drug bleomycin.

17 nt studies have shown that some conventional antineoplastic drugs can be exploited for antiangiogenic

18 tential to augment preclinical evaluation of antineoplastic drug candidates for these malignancies.

19 Here we show that the antineoplastic drug carmofur, which is used in the clini

20 effectively treat gliomas by reaching a high antineoplastic drug concentration at the target site wit

21 ationale can be proposed for intraperitoneal antineoplastic drug delivery in non-ovarian malignant di

22 l modulation of BTB permeability to increase antineoplastic drug delivery selectively to brain tumors

23 ransferases (GSTs) in cellular resistance to antineoplastic drugs, derivatives of MCF7 breast carcino

24 has been proposed as a potential target for antineoplastic drug design.

25 is has recently become a suitable target for antineoplastic drug development.

26 y may contain molecular targets suitable for antineoplastic drug discovery.

27 rmacogenomics in which ethnic differences in antineoplastic drug disposition are anticipated.

28 Doxorubicin (Dox), a cardiotoxic antineoplastic drug, disrupts the cardiac-specific progr

29 We have investigated the ability of another antineoplastic drug, dolastatin 10, in inducing Bcl2 pho

30 I) chloride hexahydrate (CoCl2.6H2O) and the antineoplastic drug doxorubicin.

31 The therapeutic efficacy of the widely used antineoplastic drugs doxorubicin, cisplatin, vincristine

32 Procedures to regulate the ordering of antineoplastic drugs for nonmalignant indications by non

33 Prices of topical antineoplastic drugs had the greatest mean absolute and

34 Moreover, the local toxicity induced by antineoplastic drugs is considered a major obstacle for

35 en paracrine IL-2 and local i.c. delivery of antineoplastic drugs is novel and may provide a combined

36 side effect associated with cancer-treating antineoplastic drugs is the development of neuropathic p

37 The efficacy of ifosfamide (IFO), an antineoplastic drug, is severely limited by a high incid

38 Several important antineoplastic drugs kill cells by increasing levels of

39 Many antineoplastic drugs kill tumor cells by inducing apopto

40 antisense ODNs in combination with standard antineoplastic drugs might be useful in reversing MDR in

41 rom the National Cancer Institute's In Vitro Antineoplastic Drug Screen to assess whether sensitivity

42 tructurally disparate DNA cleavage-enhancing antineoplastic drugs share an overlapping site of action

43 Ethonafide is an anthracene-based antineoplastic drug similar to MIT.

44 ABCG2 expression was sensitive to antineoplastic drugs since exposure to 5 muM doxorubicin

45 The antineoplastic drug sorafenib (BAY 43-9006) is a multiki

46 erythroleukemia K562 cells are resistant to antineoplastic drug (taxol)-induced apoptosis through th

47 n over the past decade, yet most preclinical antineoplastic drug testing is still reliant on conventi

48 Microtubule-damaging agents (MDA) are potent antineoplastic drugs that are widely used in clinical tr

49 It is also a target for many antineoplastic drugs that promote stabilization of coval

50 witch is a rational target for the design of antineoplastic drugs that selectively inhibit PKCepsilon

51 at, when FTI is combined with some cytotoxic antineoplastic drugs, the effects on tumor cells are add

52 and the most commonly fatal complication of antineoplastic drug therapy and may represent a serious

53 he nucleoside analogue floxuridine, a potent antineoplastic drug used in the clinic to treat advanced

54 Arabinofuranosylcytosine (Ara-C) is a potent antineoplastic drug used in the treatment of acute leuke

55 effect of difopein on cell death induced by antineoplastic drugs was examined.

56 Paclitaxel is a microtubule-targeting antineoplastic drug widely used in human cancers.

57 ristol-Myers Squibb, Princeton, NJ) is a new antineoplastic drug with broad-spectrum activity in soli

58 trophy) as well as in chemotheraputic use of antineoplastic drugs with cardiotoxic side effects (i.e.